{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:15:06Z","timestamp":1788048906964,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clim.2026.110751","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:08:41Z","timestamp":1784934521000},"page":"110751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series"],"prefix":"10.1016","volume":"287","author":[{"given":"Clothilde","family":"Gros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Rohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lef\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bardol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Bodard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safia","family":"Chebrek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Duployez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Gerfaud-Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Gaillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Guilpain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mael","family":"Heiblig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Jalaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Le Calvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Roche-Lestienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Theron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Emmanuel","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Groh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110751_bb0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00134-022-06967-9","article-title":"Epidemiology, clinical presentation, and outcomes of 620 patients with eosinophilia in the intensive care unit","volume":"49","author":"Gaillet","year":"2023","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.clim.2026.110751_bb0010","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jaip.2024.01.036","article-title":"Clinical picture, outcomes, and predictors of relapse in eosinophilia-associated coronary vasospasm: data from a European multicentric study","volume":"12","author":"Huang","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clim.2026.110751_bb0015","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.1161\/STROKEAHA.121.034191","article-title":"FIP1L1-PDGFRA-associated Hypereosinophilic syndrome as a treatable cause of watershed infarction","volume":"52","author":"Tennenbaum","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.clim.2026.110751_bb0020","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1038\/s41598-021-85852-9","article-title":"Venous thrombosis and predictors of relapse in eosinophil-related diseases","volume":"11","author":"R\u00e9au","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2026.110751_bb0025","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/clc.4960110713","article-title":"Severe constrictive pericarditis as an unsuspected cause of death in a patient with idiopathic hypereosinophilic syndrome and restrictive cardiomyopathy","volume":"11","author":"Lui","year":"1988","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.clim.2026.110751_bb0030","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How i treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110751_bb0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13023-023-02696-4","article-title":"French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes","volume":"18","author":"Groh","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clim.2026.110751_bb0040","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/cells13141180","article-title":"Managing patients with hypereosinophilic syndrome: a statement from the Italian Society of Allergy, asthma, and clinical immunology (SIAAIC)","volume":"13","author":"Caminati","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.clim.2026.110751_bb0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd3264","article-title":"Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond","volume":"10","author":"Quint\u00e1s-Cardama","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.clim.2026.110751_bb0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clim.2026.110751_bb0055","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/ajh.27306","article-title":"Involvement of the JAK-STAT pathway in the molecular landscape of tyrosine kinase fusion-negative hypereosinophilic syndromes: a nationwide CEREO study","volume":"99","author":"Groh","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clim.2026.110751_bb0060","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2015-06-654277","article-title":"Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome","volume":"127","author":"Walker","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110751_bb0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PAS.0000000000001604","article-title":"Two cases with features of lymphocyte variant Hypereosinophilic syndrome with STAT3 SH2 domain mutations","volume":"45","author":"Fernandez-Pol","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.clim.2026.110751_bb0070","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jdcr.2019.07.004","article-title":"Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib","volume":"5","author":"Damsky","year":"2019","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.clim.2026.110751_bb0075","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jaccas.2020.02.004","article-title":"A novel treatment for a rare cause of cardiogenic shock","volume":"2","author":"Chowdhury","year":"2020","journal-title":"JACC Case Rep."},{"key":"10.1016\/j.clim.2026.110751_bb0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2026.110751_bb0085","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110751_bb0090","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2026.110751_bb0095","article-title":"Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial","author":"Ogbogu","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2026.110751_bb0100","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2026.110751_bb0105","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/all.16463","article-title":"Hypereosinophilia and Hypereosinophilic syndromes: first findings from a Nationwide Multicenter cohort","volume":"80","author":"Lef\u00e8vre","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2026.110751_bb0110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.clim.2026.110751_bb0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clml.2012.09.018","article-title":"Long-term follow-up of patients with hypereosinophilic syndrome treated with alemtuzumab, an anti-CD52 antibody","volume":"13","author":"Strati","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clim.2026.110751_bb0120","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of Hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and Ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2026.110751_bb0125","doi-asserted-by":"crossref","first-page":"109275","DOI":"10.1016\/j.clim.2023.109275","article-title":"JAK inhibition for CD3- CD4+ lymphocytic-variant hypereosinophilic syndrome","volume":"251","author":"Faguer","year":"2023","journal-title":"Clin. Immunol. (Orlando)"},{"key":"10.1016\/j.clim.2026.110751_bb0130","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1093\/rheumatology\/keaf397","article-title":"Tofacitinib in combination with glucocorticoids in the treatment of eosinophilic granulomatosis with polyangiitis: a pilot study of 11 cases","volume":"64","author":"Liu","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2026.110751_bb0135","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/ced\/llag072","article-title":"JAK1 or JAK1\/2 inhibitors in drug reaction with eosinophilia and systemic symptoms: a case series","volume":"51","author":"Liu","year":"2026","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.clim.2026.110751_bb0140","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaci.2013.10.036","article-title":"Janus kinase 1\/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses","volume":"133","author":"Ashino","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2026.110751_bb0145","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients","author":"Rohmer","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clim.2026.110751_bb0150","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1016\/j.jaip.2025.09.009","article-title":"Development and validation of the FIP score for the screening of FIP1L1::PDGFRA-associated Hypereosinophilic syndrome","volume":"13","author":"Stammler","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clim.2026.110751_bb0155","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:18:59Z","timestamp":1788045539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"alternative-id":["S1521661626000896"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110751","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110751"}}